Leading the Charge

We’ve built a company poised to produce transformative pharmaceutical solutions by bringing together leaders steeped in all the functional areas needed to bring new drugs to life. With a deeply skilled management team directing our day-to-day wins, and a Board with a stellar track record, we’re acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need.

The Backbone of our Innovation

The Dova Board brings impressive experience to the table, bright minds from across the spectrum of relevant disciplines helping to illuminate the path forward for our pharmaceutical solutions.

Sean Stalfort

Sean Stalfort

Joined Dova Board: September 2016

Sean Stalfort is President of the PBM Capital Group where he sources and structures new investment opportunities, oversees many of the portfolio companies and serves on the Board of Directors for Dova Pharmaceuticals, Verrica Pharmaceuticals, Xalud Therapeutics, Tolerion, Acumen Pharmaceuticals, and Advantagene. Prior to joining PBM Capital, Sean was the Executive Vice President for New Business Development/M&A for PBM Products where he sourced and managed new growth opportunities internationally as well as various capital market activities through the sale of the company to Perrigo Corporation for over $800 million.

Sean is also a founding partner of Octagon Partners and Octagon Finance, historic tax credit real estate companies. Previously, Sean was a founding Principal and Senior Vice President of Capital Markets with Enterprise Mortgage, a specialty finance company which provided over $1.5 billion in senior cash flow debt financing to small and mid-sized companies and properties and a Vice President in Greenwich Capital’s Asset-Backed Finance Group, where he structured over $2 billion in various securitized transactions. Sean started his career as an investment banking associate at CS First Boston in New York.

Sean graduated from Brown University with a B.A. in Business Economics and Political Science.